Bim expression is reduced in human cutaneous melanomas

被引:37
作者
Dai, Derek L. [1 ]
Wang, Yemin [1 ]
Liu, Min [1 ]
Martinka, Magdalena [2 ]
Li, Gang [1 ]
机构
[1] Jack Bell Res Ctr, Dept Dermatol & Skin Sci, Vancouver, BC V6H 3Z6, Canada
[2] Univ British Columbia, Vancouver Coastal Hlth Res Inst, Dept Pathol, Vancouver, BC V5Z 1M9, Canada
关键词
D O I
10.1038/sj.jid.5700989
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Bim is a BH3-only protein belonging to the Bcl-2 family of apoptotic regulators. Upon activation, Bim can antagonize all the prosurvival Bcl-2 proteins, leading to apoptosis. To investigate whether Bim plays a role in melanoma progression, we used tissue microarray and immunohistochemistry to measure Bim expression in 52 cases of dysplastic nevi, 159 cases of primary melanomas and 52 cases of melanoma metastases, and evaluated the prognostic value of Bim expression. Our results showed that Bim expression is reduced as melanoma progresses. Significant differences for Bim staining pattern were observed between dysplastic nevi and metastatic melanomas (P < 0.001, chi(2) test), and between primary melanomas and metastatic melanomas (P < 0.001, chi(2) test). Moreover, reduced Bim expression is significantly correlated with poor 5-year survival of melanoma patients but failed to be an independent prognostic factor by Cox regression analysis. Our data suggest that Bim loss may play an important role in melanoma progression.
引用
收藏
页码:403 / 407
页数:5
相关论文
共 46 条
  • [1] Anderson C M, 1995, Oncology (Williston Park), V9, P1149
  • [2] Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system
    Balch, CM
    Soong, SJ
    Gershenwald, JE
    Thompson, JF
    Reintgen, DS
    Cascinelli, N
    Urist, M
    McMasters, KM
    Ross, MI
    Kirkwood, JM
    Atkins, MB
    Thompson, JA
    Coit, DG
    Byrd, D
    Desmond, R
    Zhang, YT
    Liu, PY
    Lyman, GH
    Morabito, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) : 3622 - 3634
  • [3] Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
    Balch, CM
    Buzaid, AC
    Soong, SJ
    Atkins, MB
    Cascinelli, N
    Coit, DG
    Fleming, ID
    Gershenwald, JE
    Houghton, A
    Kirkwood, JM
    McMasters, KM
    Mihm, MF
    Morton, DL
    Reintgen, DS
    Ross, MI
    Sober, A
    Thompson, JA
    Thompson, JF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) : 3635 - 3648
  • [4] Gene structure, alternative splicing, and chromosomal localization of pro-apoptotic Bcl-2 relative Bim
    Bouillet, P
    Zhang, LC
    Huang, DCS
    Webb, GC
    Bottema, CDK
    Shore, P
    Eyre, HJ
    Sutherland, GR
    Adams, JM
    [J]. MAMMALIAN GENOME, 2001, 12 (02) : 163 - 168
  • [5] The role of Bcl-2 family members in the progression of cutaneous melanoma
    Bush, JA
    Li, G
    [J]. CLINICAL & EXPERIMENTAL METASTASIS, 2003, 20 (06) : 531 - 539
  • [6] Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function
    Chen, L
    Willis, SN
    Wei, A
    Smith, BJ
    Fletcher, JI
    Hinds, MG
    Colman, PM
    Day, CL
    Adams, JM
    Huang, DCS
    [J]. MOLECULAR CELL, 2005, 17 (03) : 393 - 403
  • [7] BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis
    Cheng, EHYA
    Wei, MC
    Weiler, S
    Flavell, RA
    Mak, TW
    Lindsten, T
    Korsmeyer, SJ
    [J]. MOLECULAR CELL, 2001, 8 (03) : 705 - 711
  • [8] Prognostic significance of activated Akt expression in melanoma: A clinicopathologic study of 292 cases
    Dai, DL
    Martinka, M
    Li, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (07) : 1473 - 1482
  • [9] Dai DL, 2003, CLIN CANCER RES, V9, P4409
  • [10] Dhawan P, 2002, CANCER RES, V62, P7335